Clinical trial NCT02530476 (phase 1/phase 2, status: completed)
Conditions: leukemia, acute myeloid leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: selinexor, sorafenib
SMILES: FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          1. FLT3-ITD and/or FLT3-D835 mutated patients 18 years of age or older with relapsed/
             refractory AML (any number of relapses) including patients who may have been
             previously exposed to one or more FLT3-inhibitor therapies will be eligible for the
             phase I portion of this study.

          2. Phase II FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory patients: Patients
             should have a diagnosis of AML (de novo or transformed from hematologic malignancies).
             Patients with high-risk myelodysplastic syndrome (MDS) (defined as having >/= 10%
             blasts in the bone marrow) or patients with Chronic Myelomonocytic Leukemia (CMML)
             (having >/= 10% blasts in the bone marrow) may also be eligible after discussion with
             Principal Investigator (PI). The patients should have one of the following features:
             1. Patients with AML should have failed any prior induction therapy or have relapsed
             after prior therapy. 2. Patients with high-risk MDS or high-risk CMML should have
             failed any prior therapy for the MDS or CMML. 3. Patients with MDS or CMML who
             received therapy for the MDS or CMML and progress to AML are eligible at the time of
             diagnosis of AML regardless any prior therapy for AML. The World Health Organization
             (WHO) classification will be used for AML.

          3. Patients must be eligible for one of two cohorts: Cohort 1 (FLT3 and/or FLT3-D835
             inhibitor failure cohort) in FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory AML
             who have failed therapy with up to two prior salvage regimens (SCT or stem cell
             therapy for patients who previously underwent SCT/stem cell therapy in remission will
             not be considered a salvage regimen) and have previously been exposed at least one
             prior FLT3 inhibitor. Cohort 2 (FLT3 inhibitor naive cohort) in FLT3-ITD and/or
             FLT3-D835 mutated relapsed/refractory who have failed therapy with up to two prior
             salvage regimens (SCT or stem cell therapy for patients who previously underwent
             SCT/stem cell therapy in remission will not be considered a salvage regimen) with no
             prior exposure to any FLT3 inhibitor.

          4. Age >/=18 years

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status </=2

          6. Patients should have estimated life expectancy of >3 months at study entry

          7. Adequate hepatic (serum total bilirubin </= 2.0 x upper limit normal (ULN) (or </= 3.0
             x ULN if deemed to be elevated due to leukemia), alanine aminotransferase and/or
             aspartate transaminase </= 3.0 x ULN (or </= 5.0 x ULN if deemed to be elevated due to
             leukemia), and renal function (creatinine </= 2.0 mg/dL).

          8. Patients must provide written informed consent.

          9. In the absence of rapidly progressing disease, the interval from prior treatment to
             time of initiation of selinexor and sorafenib administration will be at least 2 weeks
             for cytotoxic agents or at least 5 half-lives for cytotoxic/noncytotoxic agents. The
             use of chemotherapeutic or anti-leukemic agents is not permitted during the study with
             the following exceptions: (1) intrathecal (IT) therapy for patients with controlled
             Central Nervous System (CNS) leukemia at the discretion of the PI and with the
             agreement of the Sponsor. Controlled CNS leukemia is defined by the absence of active
             clinical signs of CNS disease and no evidence of CNS leukemia on the most recent 2
             simultaneous CSF evaluations. (2) Use of one dose of cytarabine (up to 2 g/m2) or
             hydroxyurea for patients with rapidly proliferative disease is allowed before the
             start of study therapy and for the first four weeks on therapy. These medications will
             be recorded in the case-report form.

         10. Baseline ejection fraction must be >/= 40%.

         11. Females must be surgically or biologically sterile or postmenopausal (amenorrheic for
             at least 12 months) or if of childbearing potential, must have a negative serum or
             urine pregnancy test within 72 hours before the start of the treatment.

         12. Women of childbearing potential must agree to use an adequate method of contraception
             during the study and until 3 months after the last treatment. Males must be surgically
             or biologically sterile or agree to use an adequate method of contraception during the
             study until 3 months after the last treatment. Adequate methods of contraception
             include: Total abstinence when this is in line with the preferred and usual lifestyle
             of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal,
             post-ovulation methods) and withdrawal are not acceptable methods of contraception.
             Female sterilization (have had surgical bilateral oophorectomy with or without
             hysterectomy) or tubal ligation at least six weeks before taking study treatment. In
             case of oophorectomy alone, only when the reproductive status of the woman has been
             confirmed by follow up hormone level assessment

         13. (Continued from Criteria 12) Male sterilization (at least 6 months prior to
             screening). For female patients on the study, the vasectomized male partner should be
             the sole partner for that patient Combination of any of the two following (a+b or a+c
             or b+c) Use of oral, injected or implanted hormonal methods of contraception or other
             forms of hormonal contraception that have comparable efficacy (failure rate <1%), for
             example hormone vaginal ring or transdermal hormone contraception Placement of an
             intrauterine device (IUD) or intrauterine system (IUS) Barrier methods of
             contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with
             spermicidal foam/gel/film/cream/ vaginal suppository

         14. (Continued from Criteria 13) In case of use of oral contraception, women should have
             been stable on the same pill before taking study treatment. Note: Oral contraceptives
             are allowed but should be used in conjunction with a barrier method of contraception
             due to unknown effect of drug-drug interaction. Women are considered post-menopausal
             and not of child bearing potential if they have had 12 months of natural (spontaneous)
             amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of
             vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without
             hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy
             alone, only when the reproductive status of the woman has been confirmed by follow up
             hormone level assessment is she considered not of child bearing potential.

        Exclusion Criteria:

          1. Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its
             components.

          2. Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or
             psychiatric illness, which could place him/her at unacceptable risk.

          3. Patients who have had any major surgical procedure within 14 days of Day 1.

          4. Patients currently receiving any other standard or investigational therapy for the
             treatment of AML.

          5. Patients unwilling or unable to comply with the protocol.

          6. Patients receiving concomitant treatment with strong CYP3A4 inhibitors, unless such
             drugs are considered critical for the well being of the patient and not adequate
             alternatives are available. Strong CYP3A4 inhibitors include the following
             medications: itraconazole, ketoconazole, miconazole, voriconazole; amprenavir,
             atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir; ciprofloxacin,
             clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine, nefazodone,
             nicardipine, propofol, quinidine, telithromycin.

          7. Patients with any severe gastrointestinal or metabolic condition that could interfere
             with absorption of oral medications.

          8. Patients who are in blast transformation of chronic myeloid leukemia (CML). Prior MDS
             or CMML is acceptable.

          9. Patient has a concurrent active malignancy under treatment.

         10. Unstable cardiovascular function: • Symptomatic ischemia, or • Uncontrolled clinically
             significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic
             agents are excluded; 1st degree atrioventricular (AV) block or asymptomatic left
             anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded),
             or • Congestive heart failure (CHF) New York Heart Association (NYHA) Class ≥ 3, or •
             Myocardial infarction (MI) within 3 months. • Left ventricular ejection fraction < 40
             %. • Hypertension > 140 mm Hg systolic or > 90 mm Hg diastolic with or without
             antihypertensive therapy.

         11. Uncontrolled infection at the time of enrollment. Infections controlled on concurrent
             anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional
             guidelines is acceptable.

         12. Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be
             positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).

         13. Known human immunodeficiency virus (HIV) infection.

         14. Female subjects who are pregnant or breastfeeding.

         15. Acute promyelocytic leukemia.

         16. Any medical condition, which in the investigator's opinion, could compromise the
             patient's safety.